Sunil Patel - Nov 1, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Former Director
Signature
/s/ Charles Berkman, Attorney-in-Fact
Stock symbol
LGND
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4
Date filed
11/3/2022, 09:06 PM
Previous filing
Jun 13, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Disposed to Issuer -1K -3.37% 28.8K Nov 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Disposed to Issuer -4.34K -100% 0 Nov 1, 2022 Common Stock 4.34K $90.68 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sunil Patel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2 The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.